BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Papazafiropoulou A, Melidonis A. Antidiabetic agents in patients with hepatic impairment. World J Meta-Anal 2019; 7(8): 380-388 [DOI: 10.13105/wjma.v7.i8.380]
URL: https://www.wjgnet.com/1948-5182/full/v7/i8/380.htm
Number Citing Articles
Pankaj Puri, Narendra Kotwal. An Approach to the Management of Diabetes Mellitus in Cirrhosis: A Primer for the HepatologistJournal of Clinical and Experimental Hepatology 2022; 12(2): 560 doi: 10.1016/j.jceh.2021.09.010
André J. Scheen. Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive updateExpert Opinion on Drug Metabolism & Toxicology 2023; 19(8): 543 doi: 10.1080/17425255.2023.2252333
Yasuo Terauchi, Makiko Usami, Tomoyuki Inoue. The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL StudyAdvances in Therapy 2022; 39(6): 2873 doi: 10.1007/s12325-022-02121-5
M. Ganeva. SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORSTrakia Journal of Sciences 2023; 21(1): 54 doi: 10.15547/tjs.2023.01.009
Reem Al Argan, Dania Alkhafaji, Abdulmohsen Al Elq, Waleed Albaker, Yasir Elamin, Abrar Alwaheed, Mohammad Zeeshan, Zainab AlElq, Malak Alkhalifa, Rana Al Mansour, Shada Alghamdi, Abdulelah Al Ghamdi, Fatema Ismaeel, Adnan Almarzouq, Fatma Zainuddin, Reem AlSulaiman. The association between serum ferritin and bilirubin with glycemic control among patients with type 2 diabetes mellitusJournal of Medicine and Life 2023; 16(11): 1670 doi: 10.25122/jml-2023-0136
Manpreet S. Mundi, Saketh Velapati, Janki Patel, Todd A. Kellogg, Barham K. Abu Dayyeh, Ryan T. Hurt. Evolution of NAFLD and Its ManagementNutrition in Clinical Practice 2020; 35(1): 72 doi: 10.1002/ncp.10449